Serkan Kuyumcu, Emine Göknur Isik, Cömert Şen, Duygu Has-Şimsek, Bora Başaran, Zeynep Gözde Özkan, Fikret Büyükkaya, Yasemin Şanlı
{"title":"在检测头颈部鳞状细胞癌结节转移方面，[68Ga]Ga-FAPI04优于[18F]FDG PET/CT：一项单中心经验。","authors":"Serkan Kuyumcu, Emine Göknur Isik, Cömert Şen, Duygu Has-Şimsek, Bora Başaran, Zeynep Gözde Özkan, Fikret Büyükkaya, Yasemin Şanlı","doi":"10.1089/cbr.2024.0112","DOIUrl":null,"url":null,"abstract":"<p><p>This study assesses fibroblast activated protein inhibitor (FAPI) targeted PET/CT imaging against [<sup>18</sup>F]FDG PET/CT (FDG PET) for detecting nodal involvement in head and neck squamous cell carcinoma (HNSCC), intending to improve diagnostic precision for metastatic lymph nodes and lay the groundwork for future investigations. <b><i>Methods:</i></b> Patients diagnosed with HNSCC were retrospectively enrolled. All patients underwent [<sup>68</sup>Ga]Ga-FAPI04 PET/CT (FAPI PET) and FDG PET within 6 d. Primary tumor, lymph nodes, and tracer uptake were visually and quantitatively compared. The metastatic lymph nodes were evaluated using patient-and lesion-based analyses, with biopsy or postoperative histopathological examination as the reference. <b><i>Results:</i></b> The cohort includes 24 patients (17 men, 7 women; mean age 60 ± 11.8 years) who underwent FDG and FAPI PET for preoperative diagnostic workup or restaging due to known recurrence of HNSCC. Lesions included 24 primary tumors, 54 cervical lymph nodes, and 5 metastases. Primary tumors exhibited significant uptake on both PET modalities (median maximum standardized uptake value [SUV<sub>max</sub>]: FDG 19.4 ± 11.6, FAPI 16.9 ± 4.6), with no statistically significant difference (<i>p</i> > 0.5). For lymph nodes, FAPI and FDG PET showed median SUV<sub>max</sub> of 9.18 ± 6.77 and 9.67 ± 6.5, respectively. The patient-based analysis found FDG PET sensitivity at 88.2% and FAPI PET at 94.1%, with FAPI PET specificity significantly higher (85.7% vs. 42.8% for FDG PET). Lesion-based analysis revealed FAPI PET sensitivity and specificity at 84.2% and 93.7%, respectively, contrasting FDG PET's at 81.5% and 25%, respectively. <b><i>Conclusion:</i></b> This study underscores the efficacy of FAPI PET in detecting primary tumors in HNSCC. Furthermore, FAPI PET shows improved specificity over FDG PET for metastatic lymph nodes advocating further investigations for integrating FAPI PET into HNSCC clinical protocols for its enhanced precision in detecting metastatic lymph nodes.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[<sup>68</sup>Ga]Ga-FAPI04 Outperforms [<sup>18</sup>F]FDG PET/CT for Detecting Nodal Metastasis of Head and Neck Squamous Cell Carcinoma: A Single-Center Experience.\",\"authors\":\"Serkan Kuyumcu, Emine Göknur Isik, Cömert Şen, Duygu Has-Şimsek, Bora Başaran, Zeynep Gözde Özkan, Fikret Büyükkaya, Yasemin Şanlı\",\"doi\":\"10.1089/cbr.2024.0112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study assesses fibroblast activated protein inhibitor (FAPI) targeted PET/CT imaging against [<sup>18</sup>F]FDG PET/CT (FDG PET) for detecting nodal involvement in head and neck squamous cell carcinoma (HNSCC), intending to improve diagnostic precision for metastatic lymph nodes and lay the groundwork for future investigations. <b><i>Methods:</i></b> Patients diagnosed with HNSCC were retrospectively enrolled. All patients underwent [<sup>68</sup>Ga]Ga-FAPI04 PET/CT (FAPI PET) and FDG PET within 6 d. Primary tumor, lymph nodes, and tracer uptake were visually and quantitatively compared. The metastatic lymph nodes were evaluated using patient-and lesion-based analyses, with biopsy or postoperative histopathological examination as the reference. <b><i>Results:</i></b> The cohort includes 24 patients (17 men, 7 women; mean age 60 ± 11.8 years) who underwent FDG and FAPI PET for preoperative diagnostic workup or restaging due to known recurrence of HNSCC. Lesions included 24 primary tumors, 54 cervical lymph nodes, and 5 metastases. Primary tumors exhibited significant uptake on both PET modalities (median maximum standardized uptake value [SUV<sub>max</sub>]: FDG 19.4 ± 11.6, FAPI 16.9 ± 4.6), with no statistically significant difference (<i>p</i> > 0.5). For lymph nodes, FAPI and FDG PET showed median SUV<sub>max</sub> of 9.18 ± 6.77 and 9.67 ± 6.5, respectively. The patient-based analysis found FDG PET sensitivity at 88.2% and FAPI PET at 94.1%, with FAPI PET specificity significantly higher (85.7% vs. 42.8% for FDG PET). Lesion-based analysis revealed FAPI PET sensitivity and specificity at 84.2% and 93.7%, respectively, contrasting FDG PET's at 81.5% and 25%, respectively. <b><i>Conclusion:</i></b> This study underscores the efficacy of FAPI PET in detecting primary tumors in HNSCC. Furthermore, FAPI PET shows improved specificity over FDG PET for metastatic lymph nodes advocating further investigations for integrating FAPI PET into HNSCC clinical protocols for its enhanced precision in detecting metastatic lymph nodes.</p>\",\"PeriodicalId\":55277,\"journal\":{\"name\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/cbr.2024.0112\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2024.0112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
本研究评估了成纤维细胞活化蛋白抑制剂（FAPI）靶向 PET/CT 成像与[18F]FDG PET/CT （FDG PET）在检测头颈部鳞状细胞癌（HNSCC）结节受累方面的对比情况，旨在提高转移淋巴结的诊断精确度，并为今后的研究奠定基础。研究方法回顾性登记确诊为 HNSCC 的患者。所有患者均在 6 天内接受了[68Ga]Ga-FAPI04 PET/CT（FAPI PET）和 FDG PET 检查。以活检或术后组织病理学检查为参考，采用基于患者和病灶的分析方法对转移淋巴结进行评估。研究结果队列中包括 24 名患者（17 名男性，7 名女性；平均年龄为 60 ± 11.8 岁），他们接受了 FDG 和 FAPI PET 检查，以进行术前诊断或对已知复发的 HNSCC 进行重新分期。病变包括 24 个原发肿瘤、54 个颈淋巴结和 5 个转移瘤。原发性肿瘤在两种 PET 模式下均有明显摄取（中位最大标准化摄取值 [SUVmax]，FDG 19.4 ± 11）：FDG 19.4 ± 11.6，FAPI 16.9 ± 4.6），差异无统计学意义（P > 0.5）。对于淋巴结，FAPI 和 FDG PET 的中位 SUVmax 分别为 9.18 ± 6.77 和 9.67 ± 6.5。基于患者的分析发现，FDG PET 的敏感性为 88.2%，FAPI PET 为 94.1%，而 FAPI PET 的特异性明显更高（85.7% 对 FDG PET 的 42.8%）。基于病灶的分析显示，FAPI PET 的敏感性和特异性分别为 84.2% 和 93.7%，而 FDG PET 的敏感性和特异性分别为 81.5% 和 25%。结论本研究强调了 FAPI PET 检测 HNSCC 原发肿瘤的有效性。此外，与 FDG PET 相比，FAPI PET 对转移性淋巴结的特异性更高，因此建议进一步研究将 FAPI PET 纳入 HNSCC 临床方案，以提高其检测转移性淋巴结的精确度。
[68Ga]Ga-FAPI04 Outperforms [18F]FDG PET/CT for Detecting Nodal Metastasis of Head and Neck Squamous Cell Carcinoma: A Single-Center Experience.
This study assesses fibroblast activated protein inhibitor (FAPI) targeted PET/CT imaging against [18F]FDG PET/CT (FDG PET) for detecting nodal involvement in head and neck squamous cell carcinoma (HNSCC), intending to improve diagnostic precision for metastatic lymph nodes and lay the groundwork for future investigations. Methods: Patients diagnosed with HNSCC were retrospectively enrolled. All patients underwent [68Ga]Ga-FAPI04 PET/CT (FAPI PET) and FDG PET within 6 d. Primary tumor, lymph nodes, and tracer uptake were visually and quantitatively compared. The metastatic lymph nodes were evaluated using patient-and lesion-based analyses, with biopsy or postoperative histopathological examination as the reference. Results: The cohort includes 24 patients (17 men, 7 women; mean age 60 ± 11.8 years) who underwent FDG and FAPI PET for preoperative diagnostic workup or restaging due to known recurrence of HNSCC. Lesions included 24 primary tumors, 54 cervical lymph nodes, and 5 metastases. Primary tumors exhibited significant uptake on both PET modalities (median maximum standardized uptake value [SUVmax]: FDG 19.4 ± 11.6, FAPI 16.9 ± 4.6), with no statistically significant difference (p > 0.5). For lymph nodes, FAPI and FDG PET showed median SUVmax of 9.18 ± 6.77 and 9.67 ± 6.5, respectively. The patient-based analysis found FDG PET sensitivity at 88.2% and FAPI PET at 94.1%, with FAPI PET specificity significantly higher (85.7% vs. 42.8% for FDG PET). Lesion-based analysis revealed FAPI PET sensitivity and specificity at 84.2% and 93.7%, respectively, contrasting FDG PET's at 81.5% and 25%, respectively. Conclusion: This study underscores the efficacy of FAPI PET in detecting primary tumors in HNSCC. Furthermore, FAPI PET shows improved specificity over FDG PET for metastatic lymph nodes advocating further investigations for integrating FAPI PET into HNSCC clinical protocols for its enhanced precision in detecting metastatic lymph nodes.
期刊介绍：
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
